Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04102111 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease
A Phase 2 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT04102111 is a Phase 2 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 48 participants.
The verdict
NCT04102111, a Phase 2 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of JNJ-active as measured by the change in the Crohn's Disease Activity Index (CDAI) score and Simplified Endoscopic Score for Crohn's disease (SES-CD) from baseline at Week 12.
Interventions
- DRUG Placebo
- DRUG JNJ-67864238
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2019-09-23 |
| Est. Completion | 2021-12-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04102111
The ClinicalTrials.gov registry entry for NCT04102111 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04102111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04102111 about?
NCT04102111 is a clinical study titled "A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease". The purpose of this study is to evaluate the efficacy of JNJ-active as measured by the change in the Crohn's Disease Activity Index (CDAI) score and Simplified Endoscopic Score for Crohn's disease (SES-CD) from baseline at Week 12.
What is the current status of trial NCT04102111?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2019-09-23. Estimated completion is 2021-12-22.
What interventions are being tested in trial NCT04102111?
The interventions under investigation include: Placebo (DRUG), JNJ-67864238 (DRUG).
Who is sponsoring clinical trial NCT04102111?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.